|
A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome |
rufinamide |
E2080-G000-303 |
NCT01405053 EU CTR 2010-023505-36 |
Lennox-Gastaut Syndrome |
Phase 3 |
|
|
|
|
No restrictions. |
November 2017 |